ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,960,000 shares, a drop of 7.5% from the September 30th total of 3,200,000 shares. Approximately 6.2% of the company's stock are short sold. Based on an average daily trading volume, of 264,700 shares, the short-interest ratio is currently 11.2 days.
ChromaDex Price Performance
Shares of CDXC stock traded down $0.04 on Wednesday, hitting $3.58. The company's stock had a trading volume of 319,164 shares, compared to its average volume of 297,301. The stock has a market capitalization of $270.43 million, a price-to-earnings ratio of -73.20 and a beta of 1.86. ChromaDex has a fifty-two week low of $1.28 and a fifty-two week high of $4.65. The firm's fifty day moving average price is $3.48 and its 200-day moving average price is $3.22.
Insider Buying and Selling at ChromaDex
In other news, Director Kristin Patrick sold 23,000 shares of the company's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 9.64% of the company's stock.
Institutional Trading of ChromaDex
A number of institutional investors and hedge funds have recently modified their holdings of the company. Miracle Mile Advisors LLC acquired a new stake in shares of ChromaDex in the second quarter valued at about $27,000. The Manufacturers Life Insurance Company bought a new position in ChromaDex in the 2nd quarter worth approximately $31,000. Merriman Wealth Management LLC bought a new position in ChromaDex during the second quarter worth $32,000. Lazard Asset Management LLC acquired a new position in ChromaDex during the 1st quarter valued at $43,000. Finally, SG Americas Securities LLC bought a new stake in ChromaDex in the 1st quarter valued at $54,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th.
View Our Latest Report on CDXC
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
See Also
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
